ArticleNutrition & metabolism2025
Effects of Sancai Lianmei Granules in type 2 diabetes patients with metabolic dysfunction-associated fatty liver disease: a randomized prospective open-label controlled trial.
Article in Nutrition & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveSancai Lianmei granules (SCLMG) have demonstrated efficacy in improving glucolipid metabolism disorder, insulin resistance, and oxidative stress markers in both diabetic patients and rodent models. However, there is limited data available regarding the effect of SCLMG on human Metabolic dysfunction-associated fatty liver disease (MAFLD). This research aims to assess the impact of SCLMG on MAFLD in individuals with diabetes. METHODS AND RESEARCH
designSixty individuals diagnosed with type 2 diabetes mellitus (T2DM) and MAFLD were randomly allocated to one of two groups: the SCLMG group, which received standard treatment for T2DM along with SCLMG at a dose of 15 g three times daily, or the control group, which received standard treatment without SCLMG. The intervention lasted for 12 weeks. Alterations in liver fat content and liver sclerosis were evaluated using FibroScan. Secondary outcome measures included alterations in liver enzymes, fibrosis markers, advanced glycation end products AGEs, and metabolic parameters.
resultsWhen incorporated into the standard treatment regimen for MAFLD in diabetic patients, SCLMG exhibited an improvement in reducing hepatic steatosis (P = 0.048) while showing no substantial variations in liver stiffness (P = 0.762). Both the SCLMG and control groups revealed a substantial reduction in FibroScan readings at the end of the treatment period compared to baseline. The two groups exhibited substantial disparities in changes in liver enzymes (alanine aminotransferase (ALT) P = 0.018, aspartate aminotransferase (AST) P = 0.006, gamma-glutamyltranspeptidase (GGT) P < 0.001), skin autofluorescence (SAF) (P = 0.012), and metabolic parameters (P < 0.05). Nevertheless, there was a variation between the groups regarding serum procollagen III peptide (PIIIP) levels (P = 0.026), whereas changes in type Ⅳcollagen (CⅣ) (P = 0.265), hyaluronic acid (HA) (P = 0.199), laminin (LN) (P = 0.144), and high-density lipoprotein cholesterol (HDL-C) (P = 0.315) levels were not statistically significant.
conclusionsSCLMG is beneficial in regulating glucolipid metabolism and liver function. To a certain extent, SCLMG can improve liver steatosis and shows a tendency towards reducing liver sclerosis. Therefore, SCLMG has a good effect on individuals with T2DM and MAFLD.
trial registrationChiCTR2000033099|| http://www.chictr.org.cn/ 20 May 2020. REGISTRATION DETAILS AT: https://www.chictr.org.cn/hvshowprojectEN.html?id=34391&v=1.5.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.